Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-29
2011-11-22
Chung, Susannah (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S326000, C514S364000, C546S209000, C548S131000
Reexamination Certificate
active
08063034
ABSTRACT:
The present invention relates to Compounds represented by the formula (I) or salts thereof. In the formula (I), the ring A represents a benzene ring, a thiophene ring, or a pyridine ring; Rarepresents a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group; the ring B represents a pyridine ring, a pyrimidine ring, or a quinoline ring; the ring C represents a benzene ring; a pyridine ring, a quinoline ring, or an isoquinoline ring; X and Y, the same or different, represent an oxygen atom or a sulfur atom, with the proviso that the case X is a sulfur atom and Y is an oxygen atom be excluded; R1represents a hydrogen atom, a halogen atom, an amino group, a cycloalkylamino group, an alkylcarbonylamino group, an alkyloxycarbonylamino group, an alkylaminocarbonyl group, or a non-aromatic heterocyclic group; and R2and R2′, the same or different, represent a hydrogen atom, a halogen atom, an alkyl group, a halogeno-alkyl group, or a halogeno-alkoxy group.
REFERENCES:
patent: 7534802 (2009-05-01), Honda et al.
patent: 2002/0127605 (2002-09-01), Hamilton et al.
patent: 2005/0065118 (2005-03-01), Wang et al.
patent: 2006/0194836 (2006-08-01), Honda et al.
patent: 2007/0185133 (2007-08-01), Smith et al.
patent: WO 97/30035 (1997-08-01), None
patent: WO 98/35958 (1998-08-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 00/27819 (2000-05-01), None
patent: WO 01/55114 (2001-08-01), None
patent: WO 2004/052280 (2004-06-01), None
patent: WO 2005/004818 (2005-01-01), None
Patani et al, Chem. Rev., 1996, 96(8), pp. 3147-3176, esp. p. 3158.
Zarghi, et al., Chem. Pharm. Bull., 56(4), 2008, 509-512, esp. p. 510.
Ouyang et al, Bioorg. & Med. Chem. Lett., vol. 16, 2006, pp. 1191-1196.
Ouyang, et al., Bioorg. Med. Chem. Lett., vol. 16, 2206, pp. 1191-1196.
N. Shoten, “Molecular Mechanism of Symptom and Pathology”,Molecular Medicine, vol. 35, Extra Edition, pp. 73-74 (1998) (with English translation of relevant portion).
K. Shuppan, “Forefront Drug Development”,Extra Edition of Protein, Nucleic Acid, and Enzyme, pp. 1182-1187 (2000) (with English translation of relevant portion).
A.S. Kiselyov et al, “Hetaryl imidazoles: A novel dual inhibitors of VEGF receptors I and II”,Biorganic&Medicinal Chemistry Letters, 16, pp. 1440-1444 (2006).
A.S. Kiselyov et al, “Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl))ethyl)pyridine template”,Biorganic&Medicinal Chemistry Letters, 16, pp. 1913-1919 (2006).
X. Ouyang et al, “Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin of polymerization . . . ”,Biorganic&Medicinal Chemistry Letters, 16, pp. 1191-1196 (2006).
Wermuth C.G, “Molecular Variations Based on Isosteric Replacements,”Practice of Medicinal Chemistry, XX, XX, Jan. 1, 1996, pp. 203 to 237.
Supplementary European Search Report dated Apr. 1, 2011 for EP 08 70 4094.
Aono Hiroyuki
Ban Masakazu
Fujisawa Koushi
Honda Takahiro
Chung Susannah
Holtz Holtz Goodman & Chick PC
Santen Pharmaceutical Co. Ltd.
LandOfFree
Oxadiazole derivatives and thiadiazole derivatives having... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxadiazole derivatives and thiadiazole derivatives having..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxadiazole derivatives and thiadiazole derivatives having... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4289268